Advertisement

Supportive Care in Cancer

, Volume 14, Issue 6, pp 558–565 | Cite as

Anti-inflammatory agents in the management of alimentary mucositis

  • Rajesh V. LallaEmail author
  • Mark M. Schubert
  • Rene-Jean Bensadoun
  • Dorothy Keefe
Review Article

Abstract

Background

Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications.

Materials and methods

In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology conducted an evidence-based review of the literature on alimentary mucositis. The goal of this literature review was to update previously published guidelines for the management of mucositis.

Results

This article reports the findings of the subgroup charged with reviewing the literature related to anti-inflammatory interventions. Considerable preclinical and clinical evidence suggests that the use of anti-inflammatory agents may be a promising approach to reduce the severity of mucositis. However, there was not enough evidence to support any new guidelines advocating the use of any specific anti-inflammatory intervention.

Conclusion

Thus, there is a need for well-designed clinical trials evaluating the use of anti-inflammatory agents in the management of mucositis.

Keywords

Allopurinol Misoprostol Mesalazine Oral Mucositis Neck Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

The authors thank Mr. Ronald D. Hutchins, University of Texas MD Anderson Cancer Center, for conducting the literature search.

References

  1. 1.
    Abdelaal AS, Barker DS, Fergusson MM (1989) Treatment for irradiation-induced mucositis. Lancet 1:97CrossRefPubMedGoogle Scholar
  2. 2.
    Baughan CA, Canney PA, Buchanan RB et al (1993) A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol (R Coll Radiol) 5:19–24Google Scholar
  3. 3.
    Diaz A, Chepenik KP, Korn JH et al (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222–229CrossRefPubMedGoogle Scholar
  4. 4.
    Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M et al (1996) Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 17:809–812PubMedGoogle Scholar
  5. 5.
    Elting LS, Cooksley C, Chambers M et al (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539CrossRefPubMedGoogle Scholar
  6. 6.
    Epstein JB, Stevenson-Moore P (1986) Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol 62:145–148CrossRefPubMedGoogle Scholar
  7. 7.
    Epstein JB, Stevenson-Moore P, Jackson S et al (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys 16:1571–1575PubMedGoogle Scholar
  8. 8.
    Epstein JB, Gorsky M, Guglietta A et al (2000) The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89:2258–2265CrossRefPubMedGoogle Scholar
  9. 9.
    Epstein JB, Silverman S Jr, Paggiarino DA et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo- controlled clinical trial. Cancer 92:875–885CrossRefPubMedGoogle Scholar
  10. 10.
    Gibson RJ, Keefe DM, Thompson FM et al (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751–2757CrossRefPubMedGoogle Scholar
  11. 11.
    Hadorn DC, Baker D, Hodges JS et al (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754CrossRefPubMedGoogle Scholar
  12. 12.
    Hall PD, Benko H, Hogan KR et al (1995) The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 23:1256–1260PubMedGoogle Scholar
  13. 13.
    Hanson WR, Marks JE, Reddy SP et al (1995) Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. Am J Ther 2:850–857PubMedCrossRefGoogle Scholar
  14. 14.
    Hong JH, Chiang CS, Tsao CY et al (1999) Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75:1421–1427CrossRefPubMedGoogle Scholar
  15. 15.
    Johnson DJ, Scott CB, Marks JE et al (2002) Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys 54:1455–1459CrossRefPubMedGoogle Scholar
  16. 16.
    Khan AM, Birk JW, Anderson JC et al (2000) A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. Am J Gastroenterol 95:1961–1966CrossRefPubMedGoogle Scholar
  17. 17.
    Labar B, Mrsic M, Pavletic Z et al (1993) Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11:379–382PubMedGoogle Scholar
  18. 18.
    Lalla RV, Peterson DE (2005) Oral mucositis. Dent Clin North Am 49:167–184CrossRefPubMedGoogle Scholar
  19. 19.
    Leborgne JH, Leborgne F, Zubizarreta E et al (1998) Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47:145–148CrossRefPubMedGoogle Scholar
  20. 20.
    Martenson JA Jr, Hyland G, Moertel CG et al (1996) Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 35:299–303CrossRefPubMedGoogle Scholar
  21. 21.
    Matejka M, Nell A, Kment G et al (1990) Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg 28:89–91CrossRefPubMedGoogle Scholar
  22. 22.
    Miyazono Y, Gao F, Horie T (2004) Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats. Scand J Gastroenterol 39:1119–1127CrossRefPubMedGoogle Scholar
  23. 23.
    Montecucco C, Caporali R, Rossi S et al (1994) Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 37:777–778PubMedCrossRefGoogle Scholar
  24. 24.
    Nicolopoulos N, Mantidis A, Stathopoulos E et al (1985) Prophylactic administration of indomethacin for irradiation esophagitis. Radiother Oncol 3:23–25PubMedCrossRefGoogle Scholar
  25. 25.
    Northway MG, Libshitz HI, Osborne BM et al (1980) Radiation esophagitis in the opossum: radioprotection with indomethacin. Gastroenterology 78:883–892PubMedGoogle Scholar
  26. 26.
    Northway MG, Eastwood GL, Libshitz HI et al (1982) Antiinflammatory agents protect opossum esophagus during radiotherapy. Dig Dis Sci 27:923–928CrossRefPubMedGoogle Scholar
  27. 27.
    Pillsbury HC 3rd, Webster WP, Rosenman J (1986) Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryngol Head Neck Surg 112:552–553PubMedGoogle Scholar
  28. 28.
    Porta C, Moroni M, Nastasi G (1994) Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 17:246–247PubMedCrossRefGoogle Scholar
  29. 29.
    Porteder H, Rausch E, Kment G et al (1988) Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg 16:371–374PubMedGoogle Scholar
  30. 30.
    Raber-Durlacher J, Barasch A, Peterson DE et al (2004) Oral complications and management considerations in patients treated with high-dose cancer chemotherapy. Supportive Cancer Therapy 1:219–229PubMedCrossRefGoogle Scholar
  31. 31.
    Resbeut M, Marteau P, Cowen D et al (1997) A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol 44:59–63CrossRefPubMedGoogle Scholar
  32. 32.
    Rothwell BR, Spektor WS (1990) Palliation of radiation-related mucositis. Spec Care Dentist 10:21–25PubMedCrossRefGoogle Scholar
  33. 33.
    Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMedGoogle Scholar
  34. 34.
    RxKinetix, Inc., Louisville, CO (2005) RxKinetix sucessfully concludes its phase 2 trial in oral mucositis. http://www.rxkinetix.com. Cited 18 Oct 2005
  35. 35.
    Rymes N, Glick L, Holmes JA (1996) Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis. Bone Marrow Transplant 18:484PubMedGoogle Scholar
  36. 36.
    Sironi M, Pozzi P, Polentarutti N et al (1996) Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8:710–716CrossRefPubMedGoogle Scholar
  37. 37.
    Somerfield MR, Padberg JR, Pfister DG et al (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers and Current Comments 4:881–886Google Scholar
  38. 38.
    Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39–43CrossRefPubMedGoogle Scholar
  39. 39.
    Sonis ST, Peterson RL, Edwards LJ et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381CrossRefPubMedGoogle Scholar
  40. 40.
    Sonis ST, O’Donnell KE, Rishi P et al (2003) Inhibition of ceramide synthase, but not sphingomyelinase, attenuates radiation-induced mucositis in hamsters. Proc Am Soc Clin Oncol 22:747 (Abstract 3005)Google Scholar
  41. 41.
    Sonis ST, Elting LS, Keefe D et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMedGoogle Scholar
  42. 42.
    Sonis ST, O’Donnell KE, Popat R et al (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMedGoogle Scholar
  43. 43.
    Stokman MA, Spijkervet FK, Burlage FR et al (2005) Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Support Care Cancer 13:42–48CrossRefPubMedGoogle Scholar
  44. 44.
    Tanner NS, Stamford IF, Bennett A (1981) Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Br J Cancer 43:767–771PubMedGoogle Scholar
  45. 45.
    Tochner Z, Barnes M, Mitchell JB et al (1990) Protection by indomethacin against acute radiation esophagitis. Digestion 47:81–87PubMedCrossRefGoogle Scholar
  46. 46.
    Trotti A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262CrossRefPubMedGoogle Scholar
  47. 47.
    Valencia J, Velilla C, Urpegui A et al (2002) The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori 88:385–389PubMedGoogle Scholar
  48. 48.
    van’t Land B, van Beek NM, van den Berg JJ et al (2004) Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation. Dig Dis Sci 49:425–433CrossRefPubMedGoogle Scholar
  49. 49.
    Wolff JE, Hauch H, Kuhl J et al (1998) Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res 18:2895–2899PubMedGoogle Scholar
  50. 50.
    Xian CJ, Cool JC, Howarth GS et al (2002) Effects of TGF-alpha gene knockout on epithelial cell kinetics and repair of methotrexate-induced damage in mouse small intestine. J Cell Physiol 191:105–115CrossRefPubMedGoogle Scholar
  51. 51.
    Xun CQ, Thompson JS, Jennings CD et al (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83:2360–2367PubMedGoogle Scholar
  52. 52.
    Yeoh AS, Bowen JM, Gibson RJ et al (2005) Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol PhysGoogle Scholar
  53. 53.
    Yokomizo H, Yoshimatsu K, Hashimoto M et al (2004) Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 24:1131–1134PubMedGoogle Scholar
  54. 54.
    Yoshida T, Hirakata M (2003) Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis. J Rheumatol 30:2082–2083PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Rajesh V. Lalla
    • 1
    Email author
  • Mark M. Schubert
    • 2
    • 3
  • Rene-Jean Bensadoun
    • 4
  • Dorothy Keefe
    • 5
  1. 1.Department of Oral Health and Diagnostic Sciences MC1605University of Connecticut Health CenterFarmingtonUSA
  2. 2.Department of Oral MedicineUniversity of WashingtonSeattleUSA
  3. 3.Oral MedicineSeattle Cancer Care AllianceSeattleUSA
  4. 4.Department of Radiation OncologyCentre Antoine-LacassagneNiceFrance
  5. 5.Department of MedicineUniversity of AdelaideAdelaideSouth Australia

Personalised recommendations